---

Stepwise Management of Type 2 Diabetes - 50-Year-Old Female (Hypothyroidism, No HTN/IHD/CAD/CKD)

---

Patient Profile Summary

• Age: 50 years, Female
• Comorbidity: Hypothyroidism (ensure TSH optimized - uncontrolled hypothyroidism worsens insulin resistance and dyslipidemia)
• No ASCVD, HTN, IHD, CAD, CKD - this simplifies the algorithm as we do NOT need to prioritize SGLT-2 or GLP-1RA for cardioprotection as first choice

---

STEP 1 - Initial Assessment Before Starting Therapy

Key point: First optimize thyroid replacement (levothyroxine titration to TSH 0.5-2.5 mIU/L). Uncontrolled hypothyroidism independently worsens dyslipidemia, insulin resistance, and weight gain - all of which worsen diabetes management.

---

STEP 2 - Set Individualized Glycemic Targets

---

STEP 3 - Lifestyle Modification (Non-Pharmacological - Initiated from DAY 1)

a) Medical Nutrition Therapy (MNT)

• Reduce total caloric intake; target 5-10% weight loss if overweight/obese
• Low glycaemic index diet; limit refined carbohydrates and saturated fats
• Consistent carbohydrate distribution across meals
• Mediterranean or DASH dietary pattern preferred

b) Physical Activity

• 150 min/week moderate aerobic exercise (brisk walking, cycling, swimming)
• Resistance training 2-3 days/week
• Reduce prolonged sedentary time
• Stress test needed only if disease duration > 10 years before intensive activity

c) Behavioral/Lifestyle

• Weight management program if BMI > 25
• Smoking cessation
• Limit alcohol (≤1 drink/day for women)
• Diabetes self-management education and support (DSMES)
• Structured self-monitoring of blood glucose (SMBG)

---

STEP 4 - Pharmacotherapy: Stepwise Escalation

Step 4A - First-Line Monotherapy: METFORMIN

---

Step 4B - Dual Therapy: Metformin + Second Agent

• HbA1c gap from target
• Weight (overweight - prefer weight-neutral or weight-losing agents)
• Hypoglycemia risk
• Cost and patient preference
• Menopausal status (perimenopausal at 50 - TZDs may worsen bone density)

For this 50-year-old overweight/obese patient: Preferred 2nd agent is GLP-1RA (semaglutide oral 7-14 mg daily, or weekly SC dulaglutide/semaglutide) given weight reduction benefit and CV protection even as a preventive strategy. If cost is a concern, SGLT-2 inhibitor is a strong alternative.

---

Step 4C - Triple Therapy: Metformin + 2 Other Agents

• Example: Metformin + GLP-1RA + SGLT-2 inhibitor (excellent combination - complementary mechanisms, weight loss, low hypoglycemia)
• Or: Metformin + SGLT-2 inhibitor + DPP-4 inhibitor
• Or: Metformin + Sulfonylurea + DPP-4 inhibitor (if cost is the priority)

---

Step 4D - Insulin Therapy

Initiation:

• Basal insulin first: Insulin glargine (U100 or U300) or Insulin degludec
• Start: 10 units SC at bedtime OR 0.1-0.2 units/kg/day
• Titrate: Increase by 2 units every 3 days until fasting glucose 80-130 mg/dL
• Continue metformin with basal insulin (reduces insulin dose requirement and weight gain)

Intensification if needed:

• Add prandial insulin (rapid-acting: Aspart, Lispro, Glulisine) before largest meal
• Titrate to post-meal glucose targets
• "Basal-bolus" regimen: 4 injections/day - 1 basal + 3 prandial

Premixed insulin option (for simpler regimen):

• Biphasic insulin 30/70 or 70/30 BD (before breakfast and dinner)
• Less flexible but simpler for adherence

---

STEP 5 - Management of Comorbidities

Dyslipidemia (very likely with T2DM + hypothyroidism)

• Check lipids AFTER TSH is optimized - hypothyroidism-related dyslipidemia may partly resolve with euthyroid state
• If LDL remains elevated: Statin therapy - Atorvastatin 10-40 mg (moderate intensity for primary prevention at age 50 with diabetes)
• Target LDL < 100 mg/dL

Blood Pressure

• No HTN currently - monitor at every visit
• Target if BP develops: < 130/80 mmHg
• First-line if diabetes + HTN develops: ACE inhibitor or ARB (renoprotective)

Antiplatelet Therapy

• No aspirin for primary prevention in T2DM without established CVD per current ADA guidance (bleeding risk outweighs benefit)

Thyroid Management (Key Interaction)

• Maintain TSH in target range (0.5-2.5 mIU/L)
• Poorly controlled hypothyroidism → worsens insulin resistance, dyslipidemia, weight, and makes diabetes harder to control
• Levothyroxine should be taken 30-60 min before breakfast, away from metformin and other drugs that may affect absorption
• Monitor TSH every 6 months in stable diabetes + hypothyroidism

---

STEP 6 - Screening for Complications (from Diagnosis Onwards)

---

STEP 7 - Monitoring Schedule

---

Summary Flowchart for This Patient

Diagnosis of T2DM in 50F with Hypothyroidism
          ↓
STEP 1: Optimize TSH + Full metabolic work-up
          ↓
STEP 2: Set HbA1c target < 7.0%
          ↓
STEP 3: Lifestyle (diet + exercise + DSMES) - start immediately
          ↓
STEP 4A: Metformin (500mg → 2000mg) + reassess HbA1c at 3 months
          ↓ [If HbA1c not at target]
STEP 4B: Add GLP-1RA (preferred if overweight) or SGLT-2i
          ↓ [If HbA1c still not at target]
STEP 4C: Add 3rd agent (triple therapy)
          ↓ [If still failing]
STEP 4D: Add Basal Insulin (+ continue Metformin)
          ↓ [If post-meal glucose also uncontrolled]
STEP 4E: Basal-Bolus Insulin Regimen
          ↓
STEP 5: Treat dyslipidemia (statin), monitor BP, optimize thyroid
          ↓
STEP 6: Ongoing complication screening
          ↓
STEP 7: Regular monitoring (HbA1c q3 months, annual bloods/eyes/feet)

---